- Home
- AKRO
as 05-30-2025 4:00pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.9B | IPO Year: | 2019 |
| Target Price: | $82.50 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.86 - $58.40 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | May 22 '25 | Sell | $50.00 | 4,000 | $200,000.00 | 33,492 | |
| Yale Catriona | AKRO | Chief Development Officer | May 15 '25 | Sell | $39.19 | 10,000 | $392,977.81 | 102,197 | |
| Cheng Andrew | AKRO | President and CEO | May 12 '25 | Sell | $41.32 | 30,000 | $1,244,455.20 | 594,324 | |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | May 7 '25 | Sell | $42.53 | 8,000 | $339,949.95 | 33,492 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | May 6 '25 | Sell | $43.55 | 12,500 | $542,863.60 | 178,671 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Apr 24 '25 | Sell | $41.03 | 6,250 | $256,437.50 | 178,671 | |
| Yale Catriona | AKRO | Chief Development Officer | Apr 15 '25 | Sell | $38.21 | 9,073 | $343,962.22 | 102,197 | |
| Cheng Andrew | AKRO | President and CEO | Apr 10 '25 | Sell | $35.23 | 30,000 | $1,056,780.00 | 594,324 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Apr 7 '25 | Sell | $36.56 | 6,250 | $224,261.50 | 178,671 | |
| Graham G. Walmsley | AKRO | Director | Mar 25 '25 | Buy | $43.77 | 200,000 | $8,787,921.12 | 1,200,000 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Insider Monkey
10 days ago
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
MT Newswires
17 days ago
Akero Therapeutics Insider Sold Shares Worth $1,244,455, According to a Recent SEC Filing
MT Newswires
19 days ago
Akero Therapeutics Q1 Net Loss Unchanged
Insider Monkey
19 days ago
Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now
GlobeNewswire
21 days ago
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
MT Newswires
22 days ago
Akero Therapeutics Reports Positive Trial Data for Prospective Cirrhosis Drug
GlobeNewswire
22 days ago
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.